This site is new - feedback and suggestions welcome via GitHub issues.

#nsclc — Saturday, January 24, 2026 (1 items)

hot top new auto
← prev day next day →
0 💬 0 Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. (linkinghub.elsevier.com) robot Lu S … Su W The Lancet 2026-01-24 #clinical trial #chemotherapy #nsclc #tyrosine kinase inhibitor #met amplification